Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorArtac, Mehmet
dc.contributor.authorMutlu, Hasan
dc.contributor.authorSever, Ozlem
dc.contributor.authorYildirim, Mustafa
dc.date.accessioned2024-02-23T14:27:01Z
dc.date.available2024-02-23T14:27:01Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractBackground Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are class specific differences in the efficacy of Checkpoint Inhibitors (CPIs) in NSCLC, and this paper is designed to answer these clinical questions. Methods For this Meta-analysis, we searched PubMed, Science of Web, Clinicaltrials.gov and online sources for trials comparing PD-1 and PDL-1 CPIs in advanced NSCLC. The data for Hazard Ratio (HR) and their Confidence Intervals (CI) for Overall Survival (OS) was extracted. Results A sum of 9739 patients from 16 trials were included in the efficacy evaluation. For the OS endpoint, both PD-1 inhibitors (HR = 0.76, 95%CI = 0.69-0.83, P < 0.001) and PDL-1 inhibitors (HR = 0.84, 95%CI = 0.74-0.95, P < 0.001) were superior to chemotherapy in treatment naive (upfront) patients, the results were similar in treatment refractory patients (PD-1 inhibitors (HR = 0.67, 95%CI = 0.60-0.75, P < 0.001) and PDL-1 inhibitors (HR = 0.78, 95%CI = 0.69-0.88, P < 0.001) were superior to chemotherapy). There was no difference in the effect of PD-1 and PDL-1 classes of CPIs over chemotherapy in treatment naive and treatment refractory settings (Q = 1.88, df = 1, P = 0.017, and, Q = 3.27, df = 1, P = 0.070, respectively). Conclusion Efficacy of PD-1 and PDL-1 class of CPIs was not different, although differences among individual CPIs or their combinations cannot be excluded. We were also able to compute pooled efficacy data, as compared to chemotherapy alone, for trials where these groups of CPIs were utilized.en_US
dc.identifier.doi10.1177/1078155220964903
dc.identifier.endpage413en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue2en_US
dc.identifier.pmid33040676en_US
dc.identifier.scopus2-s2.0-85092446407en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage405en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220964903
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14423
dc.identifier.volume27en_US
dc.identifier.wosWOS:000578588500001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLung Canceren_US
dc.subjectMeta-Analysisen_US
dc.subjectCheckpoint Inhibitoren_US
dc.subjectPd-1 Inhibitoren_US
dc.subjectPdl-1 Inhibitoren_US
dc.subjectImmune Therapyen_US
dc.titleProgrammed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung canceren_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu